Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
Shanghai, CN
Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.72% | -5.35% | -8.74% | -0.78% | -24.75% | -7.12% | +70.55% | +47.22% | +45.84% | +45.84% | +45.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+231.6% ★ Q1'26: +184.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+6.9% Q1'26: +16.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-107.5% Q1'26: -218.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-144.5% Q1'26: -162.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-48.4% Q1'26: -41.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.45× Q1'26: -3.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
127.84M
est: 153.40M (-16.7%)
|
199.78M
est: 212.47M (-6.0%)
|
662.52M
est: 674.00M (-1.7%)
|
1.12B
1.03B – 1.20B
+65.6% YoY
|
1.41B
1.25B – 1.58B
+26.6% YoY
|
1.99B
1.85B – 2.14B
+41.2% YoY
|
| EBITDA |
-967.51M
est: -153.40M (-530.7%)
|
-892.69M
est: -212.47M (-320.2%)
|
-860.38M
est: -674.00M (-27.7%)
|
-1.12B
-1.20B – -1.03B
-65.6% YoY
|
-1.41B
-1.58B – -1.25B
-26.6% YoY
|
-1.99B
-2.14B – -1.85B
-41.2% YoY
|
| EBIT |
-1.04B
est: -153.40M (-579.2%)
|
-989.55M
est: -212.47M (-365.7%)
|
-957.24M
est: -674.00M (-42.0%)
|
-1.12B
-1.20B – -1.03B
-65.6% YoY
|
-1.41B
-1.58B – -1.25B
-26.6% YoY
|
-1.99B
-2.14B – -1.85B
-41.2% YoY
|
| Net Income |
-1.05B
est: -1.08B (+2.9%)
|
-1.04B
est: -978.16M (-6.7%)
|
-970.18M
est: -969.33M (-0.1%)
|
-764.56M
-837.80M – -691.32M
+21.1% YoY
|
-21.50M
-3.17B – 2.36B
+97.2% YoY
|
-215.59M
-236.25M – -194.94M
-902.8% YoY
|
| SGA |
368.36M
est: 812.94M (-54.7%)
|
405.20M
est: 1.13B (-64.0%)
|
184.51M
est: 3.57B (-94.8%)
|
5.91B
5.48B – 6.35B
+65.6% YoY
|
7.49B
6.62B – 8.35B
+26.6% YoY
|
10.57B
9.79B – 11.35B
+41.2% YoY
|
| EPS |
-2.64
est: -2.72 (+3.0%)
|
-2.61
est: -2.45 (-6.5%)
|
-2.43
est: -2.31 (-5.2%)
|
-1.92
-2.10 – -1.73
+17.1% YoY
|
-1.02
-7.94 – 5.91
+47.0% YoY
|
-0.54
-0.59 – -0.49
+46.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 438.0K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.5K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.7K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.61M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 21.9K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.77M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 177.1K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.6K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 7.8K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 4.2K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hai Wu | Deputy GM, President of R&D and Director | 4M | — |
| Datao Liu | Chairman, Chief Executive Officer & GM | 2M | — |
| Huiguo Hu | Senior VP, CCO, Deputy GM, Secretary of the Board & Director | 2M | male |
| Xun Gui | Vice President, Deputy GM & Director | 2M | — |
| Shu Hai Wang | Senior Vice President & CMO | — | male |
| Xi Chen | Deputy General Manager | — | female |
| Xin Du | Chief Scientific Officer & President of Maiwei (US) | — | — |
| Chunshan Tang | Executive Director | — | male |
| Yinhan Guo | Chief Research & Development Officer | — | — |
| Jinchao Zhang | Deputy General Manager | — | male |
| Jun Hua | Vice President, Chief Financial Officer & Deputy GM | — | male |
| Kwan Wai Leung | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688062.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
